This article is more than 5 years old. Information may no longer be current.
Self-administered methotrexate autoinjector confers high usability
A new self-administered methotrexate autoinjector had 90.5% subject usability, according to recently published data.
Christophe Hudry, MD, of the rheumatology department at Cochin Hospital in Paris, and colleagues conducted a study of 42 participants, which consisted of rheumatology nurses and patients with rheumatoid arthritis, who were divided into two groups according to hand disability. Each participant performed three injections with a water-filled device on a foam pad. The first injection — which the researchers defined as the first phase — was made after reading the instructions for use. The second phase comprised two injections made after explanations to the participant when in an optimum environment and then in a home environment. Researchers assessed auto-injector usability by questionnaire, with success defined as at least 75% positive response, and a score card of injection performance, with success defined as correct execution of at least 75% of steps.
Researchers found 90.5% of participants succeeded in the usability questionnaire and 95.2% succeeded in injection, with no significant difference between groups. In the second phase, all participants succeeded in the usability questionnaire and had a positive rating of injection performance, with no significant difference between environment and user group. In addition, there were no safety concerns during the study. – by Will Offit
Disclosure: Hudry reports no relevant financial disclosures. Please see the full study for a list of all other authors’ relevant financial disclosures.